Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors(†)

BACKGROUND: The use of Escherichia coli purine nucleoside phosphorylase (PNP) to activate fludarabine has demonstrated safety and antitumor activity during preclinical analysis and has been approved for clinical investigation. PATIENTS AND METHODS: A first-in-human phase I clinical trial (NCT 013101...

Full description

Saved in:
Bibliographic Details
Published in:Ann Oncol
Main Authors: Rosenthal, E. L., Chung, T. K., Parker, W. B., Allan, P. W., Clemons, L., Lowman, D., Hong, J., Hunt, F. R., Richman, J., Conry, R. M., Mannion, K., Carroll, W. R., Nabell, L., Sorscher, E. J.
Format: Artigo
Language:Inglês
Published: Oxford University Press 2015
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4560028/
https://ncbi.nlm.nih.gov/pubmed/25899782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv196
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items